Discontinued — last reported Q2 '24

Business Segments · Claims and litigation charges, net

U.S. Pharmaceutical — Claims and litigation charges, net

Analysis

StatementSegment
CategoryRisk
SignalLower is better
VolatilityVolatile
First reportedQ2 2024
Last reportedQ2 2024
Rolls up toLitigation settlement gain (loss)

How to read this metric

A decrease in charges is favorable as it reduces operational drag and legal risk, while an increase signals potential regulatory or liability headwinds.

Detailed definition

This metric captures the net financial impact of legal settlements, ongoing litigation expenses, and accruals for potent...

Peer comparison

Comparable to 'Legal reserves' or 'Litigation expenses' reported by peers in the pharmaceutical wholesale and healthcare supply chain sectors.

Metric ID: mck_segment_u_s_pharmaceutical_claims_and_litigation_charges_net

Historical Data

1 periods
 Q2 '24
Value-$57.00M

Similar Metrics at Other Companies

Johnson & Johnson logo
Johnson & JohnsonJNJView metric
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTXView metric
Altria Group logo
Altria GroupMOView metric
Johnson & Johnson logo
Johnson & JohnsonJNJView metric
CVS Health logo
CVS HealthCVSView metric
Altria Group logo
Altria GroupMOView metric

Frequently Asked Questions

What is McKesson's u.s. pharmaceutical — claims and litigation charges, net?
McKesson (MCK) reported u.s. pharmaceutical — claims and litigation charges, net of -$57.00M in Q2 2024.
What does u.s. pharmaceutical — claims and litigation charges, net mean?
The net cost incurred from legal settlements and ongoing litigation related to the business segment.